Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Oppenheimer Initiates Coverage On LeMaitre Vascular with Outperform Rating, Announces Price Target of $70

Author: Benzinga Newsdesk | September 06, 2023 04:44am
Oppenheimer analyst Suraj Kalia initiates coverage on LeMaitre Vascular (NASDAQ:LMAT) with a Outperform rating and announces Price Target of $70.

Posted In: LMAT

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist